Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Consumer Advocacy Group Presses For Cures 2.0 Revisions

Executive Summary

Consumer advocacy group Public Citizen wants US lawmakers to amend Cures 2.0 to restore the right of patients to sue medical device manufacturers, among other changes.

You may also be interested in...



MDUFA V Passed By US House Health Subcommittee

The user fee package was among several health-related bills that the subcommittee took up on Wednesday.

Cures 2.0 Would Circumvent CMS’ Pause On Breakthrough Payment Rule, Improve Telehealth, And More

A new medical research bill proposed by US lawmakers would push through a delayed but highly anticipated CMS policy requiring payment for breakthrough devices.

Device Industry Groups Lobby Against Bill That Would End PMA Pre-emption

Device industry groups are working to persuade lawmakers that a Supreme Court decision protecting device makers from personal injury suits involving PMA-approved devices should stand

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT145123

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel